ArticleFrontiers in endocrinology2026
A malignancy risk prediction model for Bethesda category III thyroid nodules based on serological indicators, C-TIRADS, and BRAF V600E testing.
Wei Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.